學術活動
2025.09.19 | by 秘書處 秘書處
【線上課程、請先報名】Navigating the New Treatment Landscape of BRAF V600E-mutant mCRC: Real Cases with Real Solutions
【線上課程、請先報名】Navigating the New Treatment Landscape of BRAF V600E-mutant mCRC: Real Cases with Real Solutions
主辦單位：高雄市胃腸道腫瘤關懷協會
協辦單位：臺灣皮耶法柏股份有限公司
時 間：114年9月19日（週五）19:00-20:40
地 點：實體+線上直播會議
報名連結 https://www.medtalks.com.tw/TrendsTube/Default_Home.aspx?EventLiveID=834
認定積分：本會醫師會員5分
欲參加實體會議，請先洽07-3121101分機5575方小姐。
BRAF V600E-mutant metastatic colorectal cancer (mCRC) is a particularly aggressive subtype of CRC with poor prognosis. BRAF V600E-mutant mCRC is more likely to be associated with higher disease burden and less responsive to the 1L traditional systemic therapy. Thus, BRAF V600E-mutant mCRC was unlikely to receive conversion surgery in the past. Recently, emerging new treatment options has revolutionary changed the treatment landscape of BRAF V600E-mutant mCRC, which can provide higher response rate and more durable PFS, provide a higher chance for BRAF V600E-mutant mCRC patients to receive conversion surgery. The role of conversion surgery in some subgroups is particularly an area that is under explore, such as liver oligometastasis. Further more, there is no established reference guiding the treatment options if patients progressed from novel regimen. Switching regimen and then considering re-challenge BRAF combination could be an approach since later line options do not provide optimal ORR and PFS. Treatment beyond progression could be an option as well, however, may require guidance from NGS result.
主辦單位：高雄市胃腸道腫瘤關懷協會
協辦單位：臺灣皮耶法柏股份有限公司
時 間：114年9月19日（週五）19:00-20:40
地 點：實體+線上直播會議
報名連結 https://www.medtalks.com.tw/TrendsTube/Default_Home.aspx?EventLiveID=834
認定積分：本會醫師會員5分
欲參加實體會議，請先洽07-3121101分機5575方小姐。
BRAF V600E-mutant metastatic colorectal cancer (mCRC) is a particularly aggressive subtype of CRC with poor prognosis. BRAF V600E-mutant mCRC is more likely to be associated with higher disease burden and less responsive to the 1L traditional systemic therapy. Thus, BRAF V600E-mutant mCRC was unlikely to receive conversion surgery in the past. Recently, emerging new treatment options has revolutionary changed the treatment landscape of BRAF V600E-mutant mCRC, which can provide higher response rate and more durable PFS, provide a higher chance for BRAF V600E-mutant mCRC patients to receive conversion surgery. The role of conversion surgery in some subgroups is particularly an area that is under explore, such as liver oligometastasis. Further more, there is no established reference guiding the treatment options if patients progressed from novel regimen. Switching regimen and then considering re-challenge BRAF combination could be an approach since later line options do not provide optimal ORR and PFS. Treatment beyond progression could be an option as well, however, may require guidance from NGS result.
【附件下載】
TOP
學分查詢
線上報名
專科訓練
線上繳費